Editorial

  • HOME
  • ARTICLE CATEGORY
  • Editorial
Editorial
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
Hyo-Cheol Kim
Clin Mol Hepatol. 2023;29(4):984-986.   Published online August 14, 2023
View: 1150   Download: 28
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clin Mol Hepatol. 2023;29(4):980-983.   Published online August 16, 2023
View: 1222   Download: 75
Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
Sang Min Yoon
Clin Mol Hepatol. 2023;29(4):977-979.   Published online August 31, 2023
View: 939   Download: 36
Adding to the confusion in more than just the name
Jacob George
Clin Mol Hepatol. 2023;29(4):973-976.   Published online September 18, 2023
View: 1135   Download: 57  Crossref: 2
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
Clin Mol Hepatol. 2023;29(3):690-692.   Published online May 30, 2023
View: 1551   Download: 76  Web of Science: 1  Crossref: 1
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol. 2023;29(2):414-416.   Published online February 28, 2023
View: 3737   Download: 61
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):411-413.   Published online March 6, 2023
View: 1799   Download: 43  Web of Science: 1  Crossref: 1
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Ji-Won Park, Ki Tae Suk
Clin Mol Hepatol. 2023;29(2):408-410.   Published online March 16, 2023
View: 1984   Download: 63  Web of Science: 1  Crossref: 1
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clin Mol Hepatol. 2023;29(2):404-407.   Published online March 14, 2023
View: 2234   Download: 65  Web of Science: 2  Crossref: 2
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Kee-Huat Chuah, Wah-Kheong Chan
Clin Mol Hepatol. 2023;29(2):401-403.   Published online February 28, 2023
View: 2089   Download: 53  Crossref: 1
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clin Mol Hepatol. 2023;29(2):398-400.   Published online February 13, 2023
View: 2369   Download: 109
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clin Mol Hepatol. 2023;29(2):394-397.   Published online April 1, 2023
View: 2168   Download: 76
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clin Mol Hepatol. 2023;29(2):390-393.   Published online March 20, 2023
View: 2112   Download: 52  Web of Science: 2  Crossref: 2
Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2023;29(2):384-389.   Published online March 14, 2023
View: 2465   Download: 71  Web of Science: 1  Crossref: 1
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2023;29(2):377-380.   Published online March 9, 2023
View: 2035   Download: 89  Web of Science: 1  Crossref: 1
The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clin Mol Hepatol. 2023;29(2):374-376.   Published online March 6, 2023
View: 1962   Download: 61
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):367-370.   Published online March 20, 2023
View: 2096   Download: 57  Web of Science: 3  Crossref: 2
1795
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2023;29(2):363-366.   Published online March 9, 2023
View: 2179   Download: 76  Web of Science: 1  Crossref: 1
1802
The current trends in the health burden of primary liver cancer across the globe
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(2):358-362.   Published online March 14, 2023
View: 2267   Download: 52
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):355-357.   Published online March 9, 2023
View: 2437   Download: 81  Web of Science: 6  Crossref: 7
Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
San-Chi Chen
Clin Mol Hepatol. 2023;29(2):352-354.   Published online March 20, 2023
View: 2138   Download: 58
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
Shen-Yung Wang
Clin Mol Hepatol. 2023;29(2):349-351.   Published online March 20, 2023
View: 2099   Download: 51
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(2):345-348.   Published online March 9, 2023
View: 2083   Download: 53
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
Clin Mol Hepatol. 2023;29(2):342-344.   Published online March 16, 2023
View: 2290   Download: 52  Web of Science: 1  Crossref: 2
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Shan Shan, Jidong Jia
Clin Mol Hepatol. 2023;29(2):339-341.   Published online March 16, 2023
View: 2310   Download: 84  Crossref: 1
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
Do Young Kim
Clin Mol Hepatol. 2023;29(2):335-338.   Published online March 20, 2023
View: 2118   Download: 48
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clin Mol Hepatol. 2023;29(2):332-334.   Published online March 16, 2023
View: 2051   Download: 43

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 805
TOTAL : 1680035
Close layer